Arkolith/Insider Trading/NAMS/Form 4

Lange Louis G

DirectorNewAmsterdam Pharma Co N.V. (NAMS) · full profile →Form 4 · filed Mar 10, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$829K
Net Open-Market Flow
-$829K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(X)45K$11.50$513K55K
Mar 6, 2026Sell(S)28K$29.41$829K0

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Mar 9, 2026Option exercise(X)45K—$00

Transaction Codes

X
Exercise of in-the-money derivative
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001193125-26-100798) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML